These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 23535846)

  • 1. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
    Hölzel M; Bovier A; Tüting T
    Nat Rev Cancer; 2013 May; 13(5):365-76. PubMed ID: 23535846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
    Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
    Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.
    Landsberg J; Kohlmeyer J; Renn M; Bald T; Rogava M; Cron M; Fatho M; Lennerz V; Wölfel T; Hölzel M; Tüting T
    Nature; 2012 Oct; 490(7420):412-6. PubMed ID: 23051752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma immunotherapy: strategies to overcome pharmacological resistance.
    Trojaniello C; Vitale MG; Scarpato L; Esposito A; Ascierto PA
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):289-304. PubMed ID: 32195606
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cells and targeted approaches to melanoma cure.
    Murphy GF; Wilson BJ; Girouard SD; Frank NY; Frank MH
    Mol Aspects Med; 2014 Oct; 39():33-49. PubMed ID: 24145241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory regulation of stem-like cells in melanoma.
    Lim MS; Wang JH; Power DG; Redmond HP
    Melanoma Res; 2017 Feb; 27(1):1-7. PubMed ID: 27764061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis.
    Hölzel M; Tüting T
    Trends Immunol; 2016 Jun; 37(6):364-374. PubMed ID: 27151281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy.
    Zhang S; Yang Z; Qi F
    Mol Biol Rep; 2020 Feb; 47(2):1435-1443. PubMed ID: 31838656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
    Clara JA; Monge C; Yang Y; Takebe N
    Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor immunity and cancer stem cells.
    Schatton T; Frank MH
    Ann N Y Acad Sci; 2009 Sep; 1176():154-69. PubMed ID: 19796244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatio-Genetic and phenotypic modelling elucidates resistance and re-sensitisation to treatment in heterogeneous melanoma.
    Hodgkinson A; Le Cam L; Trucu D; Radulescu O
    J Theor Biol; 2019 Apr; 466():84-105. PubMed ID: 30503930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer stem cells and human malignant melanoma.
    Schatton T; Frank MH
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):39-55. PubMed ID: 18353142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications.
    Marzagalli M; Raimondi M; Fontana F; Montagnani Marelli M; Moretti RM; Limonta P
    Semin Cancer Biol; 2019 Dec; 59():221-235. PubMed ID: 31265892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
    Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
    Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
    Mandalà M; Massi D
    Handb Exp Pharmacol; 2018; 249():129-143. PubMed ID: 28238077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
    Margolin K
    Curr Treat Options Oncol; 2016 Sep; 17(9):48. PubMed ID: 27461037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.